Tropomyosin receptor kinase C
Tropomyosin receptor kinase C (TrkC), also known as NT-3 growth factor receptor, is a protein that in humans is encoded by the NTRK3 gene. TrkC is a member of the tropomyosin receptor kinase (Trk) family of tyrosine kinase receptors, which are key regulators in the development and maintenance of the nervous system. TrkC specifically binds to and is activated by neurotrophin-3 (NT-3).
Function[edit | edit source]
TrkC plays a critical role in the development and function of the nervous system. It is involved in the differentiation and survival of certain neuronal populations during development. Upon binding with its ligand, NT-3, TrkC dimerizes and undergoes autophosphorylation, which activates its kinase activity. This activation leads to the phosphorylation of downstream signaling molecules and the activation of signaling pathways that promote neuronal survival, growth, and differentiation.
Structure[edit | edit source]
The structure of TrkC includes an extracellular domain, which binds to NT-3, a single transmembrane domain, and an intracellular domain that contains the tyrosine kinase activity. The extracellular domain consists of several leucine-rich repeats and cysteine clusters, which are characteristic of the Trk family of receptors.
Clinical Significance[edit | edit source]
Alterations in the expression or function of TrkC have been implicated in various neurological disorders and diseases. Overexpression of TrkC has been observed in certain types of cancer, suggesting a potential role in tumorigenesis. Conversely, loss of TrkC function may contribute to neurodegenerative diseases due to the reduced survival of neurons that depend on NT-3/TrkC signaling.
Research[edit | edit source]
Research on TrkC has focused on understanding its role in the nervous system and exploring its potential as a therapeutic target in neurological disorders and cancer. Studies have investigated the use of TrkC agonists or NT-3 mimetics to promote neuronal survival and regeneration in various models of neurodegenerative diseases. Additionally, inhibitors of TrkC kinase activity are being explored for their potential to inhibit the growth of TrkC-expressing tumors.
| Tropomyosin receptor kinase C Resources | |
|---|---|
|
 |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
